There have been multiple systemic innovations that have improved how we treat non-small cell lung cancer (NSCLC). First came targeted therapies in the 1970s and 1980s and then immunotherapies, which first entered the market roughly a decade ago. More recently, surgical robots have enabled better nodule removal.
OncoHost’s CEO Is PROphet-ic About His Diagnostic’s Potential To Transform Care
Medtech Insight spoke to Ofer Sharon, CEO of OncoHost, about his company’s PROphet platform, proving a diagnostic’s ability to improve cancer survival, and the slipperiness of involving oneself with pharma.
